We dedicate this book to our patients and their families. We thank the authors of each chapter for their expertise and contributions to complete the third edition of *Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice*. We also appreciate the thoughtful comments from the field reviewers.

I thank my husband, Kevin, and children, Christopher and Megan, for their love and encouragement that supported me throughout this project. I also thank my colleagues at my work and across the country for their support and the work that they do for our patients.

—Kim Schmit-Pokorny

In addition, I thank Rosemary Ford for her unwavering passion for hematopoietic stem cell transplantation nursing practice and education, as well as for her invaluable guidance and mentorship.

—Seth Eisenberg
Contributors

Editors

Kim Schmit-Pokorny, RN, MSN, OCN®, BMTCN®
Manager, Blood and Marrow Transplant Program
Nebraska Medicine
Omaha, Nebraska
Chapter 5. Stem Cell Collection

Seth Eisenberg, RN, ADN, OCN®, BMTCN®
Professional Practice Coordinator, Infusion Services
Seattle Cancer Care Alliance
Seattle, Washington
Chapter 10. Hepatorenal and Bladder Complications

Authors

Jody B. Acheson, RN, DNP, MPH, OCN®, BMTCN®
Bone Marrow Transplant/Hematologic Malignancies Program Manager
St. Luke’s Cancer Institute
Boise, Idaho
Chapter 4. Considerations in Program Development and Sites of Care

Shelley Burcat, MSN, RN, AOCNS®, CCCTM
Clinical Nurse Specialist
Philadelphia, Pennsylvania
Chapter 3. Current Research

Katherine Byar, MSN, APN, BC, BMTCN®
Nurse Practitioner
Nebraska Medicine
Omaha, Nebraska
Chapter 6. Transplant Treatment Course and Acute Complications

Suni Dawn Elgar, MPH, BSN, RN, OCN®
Associate Director of Clinical Operations, Apheresis, Blood and Marrow Transplant, Hematology, and Immunotherapy
Seattle Cancer Care Alliance
Seattle, Washington
Chapter 13. Relapse and Subsequent Malignancies

Kelly A. Hofstra, RN, BSN, OCN®, BMTCN®
Program Coordinator
St. Luke’s Cancer Institute
Boise, Idaho
Chapter 4. Considerations in Program Development and Sites of Care

Keriann Kordas, MSN, APN
Advanced Practice Provider, Hematology/Oncology, Cellular Therapy
University of Chicago Medicine
Chicago, Illinois
Chapter 12. Neurologic Complications

Martha Lassiter, RN, MSN, AOCNS®, BMTCN®
Clinical Nurse Specialist
Division of Cellular Therapy and Hematologic Malignancies
Duke University Health System
Durham, North Carolina
Chapter 1. Overview of Hematopoiesis and Immunology

Theresa Latchford, RN, MS, BMTCN®, AOCNS®
Oncology Clinical Nurse Specialist
Stanford Health Care
Stanford, California
Chapter 16. Emerging Cellular Therapies: Chimeric Antigen Receptor T Cells

Rebecca Martin, BSN, RN, OCN®, BMTCN®
Staff Registered Nurse/Educator
Froedtert Hospital, Medical College of Wisconsin
Milwaukee, Wisconsin
Chapter 9. Gastrointestinal Complications

Sandra A. Mitchell, PhD, CRNP, AOCN®
Research Scientist, Outcomes Research Branch
Nurse Practitioner, Chronic Graft-Versus-Host Disease Clinic and Study Group
National Cancer Institute
Rockville, Maryland
Chapter 7. Acute and Chronic Graft-Versus-Host Disease

Joyce L. Neumann, PhD, APRN, AOCN®, BMTCN®
Program Director, Stem Cell Transplantation and Cellular Therapy
Adjuvant Ethicist, Section of Integrated Ethics
University of Texas MD Anderson Cancer Center
Houston, Texas
Chapter 15. Ethical Considerations

Kimberly A. Noonan, DNP, ANP-BC, AOCN®
Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts
Chapter 9. Gastrointestinal Complications

Rebecca Pape, MSN, APN, FNP-C
Advanced Practice Provider, Hematology/Oncology, Cellular Therapy
University of Chicago Medicine
Chicago, Illinois
Chapter 12. Neurologic Complications
Editors and authors of books and guidelines provided by the Oncology Nursing Society are expected to disclose to the readers any significant financial interest or other relationships with the manufacturer(s) of any commercial products.

A vested interest may be considered to exist if a contributor is affiliated with or has a financial interest in commercial organizations that may have a direct or indirect interest in the subject matter. A “financial interest” may include, but is not limited to, being a shareholder in the organization; serving on an organization’s speakers bureau; or receiving research funding from the organization. An “affiliation” may be holding a position on an advisory board or some other role of benefit to the commercial organization. Vested interest statements appear in the front matter for each publication.

Contributors are expected to disclose any unlabeled or investigational use of products discussed in their content. This information is acknowledged solely for the information of the readers.

The contributors provided the following disclosure and vested interest information:

Kim Schmit-Pokorny, RN, MSN, OCN®, BMTCN®, Juno Therapeutics, Kite Pharma, Novartis, consultant or advisory role, honoraria
Seth Eisenberg, RN, ADN, OCN®, BMTCN®, B. Braun Medical, Genentech, ICU Medical, United States Pharmacopeia, consultant or advisory role; ICU Medical, honoraria
Katherine Byar, MSN, APN, BC, BMTCN®, Creative Educational Concepts, honoraria
Keriann Kordas, MSN, APN; Kite Pharma, consultant or advisory role; Merck, honoraria
Theresa Latchford, RN, MS, BMTCN®, AOCNS®; Kite Pharma, honoraria
Rebecca Martin, BSN, RN, OCN®, BMTCN®; Jazz Pharmaceuticals, honoraria
Kimberly A. Noonan, DNP, ANP-BC, AOCN®, Celgene, consultant or advisory role
Pamela D. Paplham, DNP, AOCNP®, FNP-BC, FAANP; American Society for Transplantation and Cellular Therapy, honoraria
D. Kathryn Tierney, RN, BMTCN®, PhD; American Society for Transplantation and Cellular Therapy, Oncology Nursing Society, honoraria
Licensing Opportunities

The Oncology Nursing Society (ONS) produces some of the most highly respected educational resources in the field of oncology nursing, including ONS’s award-winning journals, books, online courses, evidence-based resources, core competencies, videos, and information available on the ONS website at www.ons.org. ONS welcomes opportunities to license reuse of these intellectual properties to other organizations. Licensing opportunities include the following:

• **Reprints**—Purchase high-quality reprints of ONS journal articles, book chapters, and other content directly from ONS, or obtain permission to produce your own reprints.

• **Translations**—Translate and then resell or share ONS resources internationally.

• **Integration**—Purchase a license to incorporate ONS’s oncology-specific telephone triage protocols or other resources into your institution’s EMR or EHR system.

• **Cobranding**—Display your company’s logo on ONS resources for distribution to your organization’s employees or customers.

• **Educational reuse**—Supplement your staff or student educational programs using ONS resources.

• **Customization**—Customize ONS intellectual property for inclusion in your own products or services.

• **Bulk purchases**—Buy ONS books and online courses in high quantities to receive great savings compared to regular pricing.

As you read through the pages of this book, think about whether any of these opportunities are the right fit for you as you consider reusing ONS content—and the contents of this book—for your organization.

Contact licensing@ons.org with your licensing questions or requests.
# Contents

## PREFACE

11

## CHAPTER 1. OVERVIEW OF HEMATOPOIESIS AND IMMUNOLOGY

1

- Introduction .................................................................................. 1
- Hematopoiesis and Immunology Across the Life Span .................. 2
- Hematopoietic Structure and Function ....................................... 5
- Immune Function: Cells and Responses .................................. 7
- Organs of the Immune System ................................................. 9
- Summary ..................................................................................... 9
- References .................................................................................. 9

## CHAPTER 2. BASIC CONCEPTS OF TRANSPLANTATION

13

- Introduction .................................................................................. 13
- Types of Hematopoietic Stem Cell Transplants ......................... 14
- Nonmyeloablative Hematopoietic Stem Cell Transplantation ........ 15
- Sources of Stem Cells .................................................................. 15
- Be The Match (National Marrow Donor Program) ...................... 17
- Preparative Regimens ................................................................. 17
- Clinical Evaluation .................................................................. 18
- Patient and Family Education .................................................... 19
- Summary ..................................................................................... 21
- References .................................................................................. 21

## CHAPTER 3. CURRENT RESEARCH

23

- Introduction .................................................................................. 23
- Clinical Trials ............................................................................. 23
- Scientific Review Committee .................................................... 23
- Institutional Review Board ....................................................... 24
- National Cancer Institute National Clinical Trials Network ........ 25
- Resources for Clinical Investigation in Blood and Marrow ......... 26
- Transplantation .......................................................................... 30
- Nursing Research ....................................................................... 32
- Gene Therapy ............................................................................ 32
- Nonmalignant Diseases Treated With Hematopoietic Stem Cell Transplantation ......................................................... 44
- Summary ..................................................................................... 54
- References .................................................................................. 54

## CHAPTER 4. CONSIDERATIONS IN PROGRAM DEVELOPMENT AND SITES OF CARE

63

- Introduction .................................................................................. 63
- Initial Program Development ..................................................... 63
- Care Continuum ........................................................................... 64
- Interprofessional Team ............................................................... 67
- Nurse Leadership ........................................................................ 72
- Transplant Nurses and Professional Development .................... 74
- Resource Utilization ................................................................... 75
- Caregiver Support ....................................................................... 76
- Professional Transplant Community ......................................... 77
- Quality Management ................................................................. 77
- Accreditation, Regulation, and the Quality Plan ......................... 77
- Outcomes: Data, Reporting, and the Stem Cell Therapeutic Outcomes Database .......................................................... 79
- Summary ..................................................................................... 79
- References .................................................................................. 79

## CHAPTER 5. STEM CELL COLLECTION

85

- Introduction .................................................................................. 85
- Evaluation of Autologous and Allogeneic Donors for Collection ... 85
- Bone Marrow Harvest ................................................................ 85
- Peripheral Blood Stem Cell Collection ...................................... 89
- Mobilization of Stem Cells ....................................................... 90
- Apheresis Issues ............................................................... 96
- Allogeneic Blood Stem Cell Collection .................................... 99
- Unrelated Blood Stem Cell Collection ..................................... 101
- Mismatched and Haploidentical Donors ................................. 101
- Pediatric Blood Stem Cell Collection ..................................... 102
- Psychological and Ethical Issues Related to Stem Cell Donation . 102
- Cord Blood Stem Cell Transplantation .................................... 103
- Stem Cell Processing ............................................................. 105
- Stem Cell Manipulation .......................................................... 105
- Future Directions .............................................................. 105
- Summary ..................................................................................... 106
- References .................................................................................. 106

## CHAPTER 6. TRANSPLANT TREATMENT COURSE AND ACUTE COMPLICATIONS

111

- Introduction .................................................................................. 111
- Conditioning Regimens for Hematopoietic Stem Cell Transplantation ................................................................. 111
- Cellular Infusion of Hematopoietic Stem Cells ......................... 119
- After Stem Cell Infusion ......................................................... 121
- Engraftment Phase ............................................................ 128
- Patient and Caregiver Education ............................................. 130
- Summary ..................................................................................... 130
- References .................................................................................. 131

## CHAPTER 7. ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE

133

- Introduction .................................................................................. 133
- Definitions ................................................................................. 133
- Acute Graft-Versus-Host Disease ........................................... 134
- Chronic Graft-Versus-Host Disease ......................................... 141
- Preventing and Treating Acute and Chronic Graft-Versus-Host Disease ................................................................. 148
- Strategies for Prophylaxis and Treatment ................................. 161
- Components of Supportive Care .......................................... 164
Hematopoietic stem cell transplantation (HSCT) has evolved into a treatment option for many types of diseases, and indications for HSCT continue to expand. The term HSCT will be used to identify transplantation throughout the book. The reader must read carefully to determine if the source of stem cells is autologous, syngeneic, or allogeneic; if the stem cells are collected from the bone marrow, peripheral blood, or umbilical cord blood; and if the preparative regimen is myeloablative or nonmyeloablative.

This publication was preceded by nursing manuals related to bone marrow (1994) and peripheral blood stem cell transplantation (1997) that were published by the Oncology Nursing Society (ONS). Many institutions used these books as guidelines for nursing practice and education. For many years, HSCT was seen as highly experimental treatment as pioneers in the field sought to improve outcomes and look for innovative ways to mitigate side effects. As a result of this research, standards have emerged for medicine and nursing practice, which ultimately paved the way for certification.

The first and second editions of Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice were published by ONS in 2004 and 2013, respectively. We thank the previous editor, Susan Ezzone, for her work as editor on both editions. In this edition, we want to continue to promote the expansion and dissemination of knowledge regarding HSCT for nurses working in the specialty and nurses caring for patients prior to and after transplantation. The specialty of HSCT and nursing practice continues to grow and evolve. As editors, we hope this publication will be a valuable educational resource for nurses caring for patients as they journey through the HSCT continuum.